Significance of maternal screening for toxoplasmosis, rubella, cytomegalovirus and herpes simplex virus infection in cases of fetal growth restriction

Journal of Obstetrics and Gynaecology Research

Volumn 39, Issue 3, 2013, Pages 653-657

  Yamamoto, Ryo ^a   Ishii, Keisuke ^a   Shimada, Mayumi ^a   Hayashi, Syusaku ^a   Hidaka, Nobuhiro ^a   Nakayama, Masahiro ^a   Mitsuda, Nobuaki ^a  

^a RESEARCH INSTITUTE FOR MATERNAL AND CHILD HEALTH   (Japan)

Author keywords

Congenital infection; Cytomegalovirus; Fetal growth restriction; Maternal TORCH test

Indexed keywords

VIRUS DNA;

ADULT; AMNION FLUID; ARTICLE; CONGENITAL INFECTION; CYTOMEGALOVIRUS INFECTION; FEMALE; FETUS; HERPES SIMPLEX; HUMAN; INTRAUTERINE GROWTH RETARDATION; MAJOR CLINICAL STUDY; PLACENTA; POLYMERASE CHAIN REACTION; PREGNANCY OUTCOME; RUBELLA; TORCH PANEL ELISA KIT; TOXOPLASMOSIS; ULTRASOUND;

ADOLESCENT; ADULT; CYTOMEGALOVIRUS INFECTIONS; FEMALE; FETAL GROWTH RETARDATION; HERPES SIMPLEX; HUMANS; INFANT, NEWBORN; MALE; MASS SCREENING; PREGNANCY; RUBELLA; SEROLOGIC TESTS; TOXOPLASMOSIS, CONGENITAL; YOUNG ADULT;

EID: 84875264329     PISSN: 13418076     EISSN: 14470756     Source Type: Journal    
DOI: 10.1111/j.1447-0756.2012.02012.x     Document Type: Article

References (28)

1. Klein JO, Remington JS. Current concepts of infections of the fetus and newborn infant. Infectious Diseases of the Fetus and Newborn Infant 4th edn. 1995: 1.
2. Nahmias AJ, Walls KW, Stewart JA. The TORCH complexperinatal infections associated with toxoplasma and rubella, cytomegalo-and herpes simplex viruses. Pediatr Res 1971; 5: 405-406.
3. American College of Obstetricians and Gynecologists. Intrauterine growth restriction. Practice Bulletin No.12. January 2000.
4. From the NIH: TORCH package antibody tests not recommended for routine screening of pregnant women. JAMA 1982; 247: 2477-2478.
5. Cullen A, Brown S, Cafferkey M, O'Brien N, Griffin E. Current use of the TORCH screen in the diagnosis of congenital infection. J Infect 1998; 36: 185-188.
6. Khan NA, Kazzi SN. Yield and costs of screening growthretarded infants for torch infections. Am J Perinatol 2000; 17: 131-135.
7. Shinozuka N. Fetal biometry and fetal weight estimation: JSUM standardization. Ultrasound Rev Obst Gynecol 2002; 2: 156-161.
8. Gilbert RE, Peckham CS. Congenital toxoplasmosis in the United Kingdom: To screen or not to screenJ Med Screen 2002; 9: 135-141.
9. Guerina NG, Hsu HW, Meissner HC et al. Neonatal serologic screening and early treatment for congenital Toxoplasma gondii infection. The New England Regional Toxoplasma Working Group. N Engl J Med 1994; 330: 1858-1863.
10. Varella IS, Canti IC, Santos BR et al. Prevalence of acute toxoplasmosis infection among 41,112 pregnant women and the mother-to-child transmission rate in a public hospital in South Brazil. Memorias do Instituto Oswaldo Cruz 2009; 104: 383-388.
11. Hohlfeld P, MacAleese J, Capella-Pavlovski M, Giovangrandi Y, Thulliez P, Forestier F. Fetal toxoplasmosis: Ultrasonographic signs. Ultrasound Obstet Gynecol 1991; 1: 241-244.
12. Freeman K, Oakley L, Pollak A, Buffolano W, Petersen E, Semprini AE. Association between congenital toxoplasmosis and preterm birth, low birthweight and small for gestational age birth. BJOG 2005; 112: 31-37.
13. Marquez L, Levy ML, Munoz FM, Palazzi DL. A report of three cases and review of intrauterine herpes simplex virus infection. Pediatr Infect Dis J 2011; 30: 153-157.
14. Diguet A, Patrier S, Eurin D, Chouchene S, Marpeau L, Laquerriere A. Prenatal diagnosis of an exceptional intrauterine herpes simplex type 1 infection. Prenat Diagn 2006; 26: 154-157.
15. Epps RE, Pittelkow MR, Su WP. TORCH syndrome. Semin Dermatol 1995; 14: 179-186.
16. Reef SE, Frey TK, Theall K, Abernathy E, Burnett CL, Icenogle J. The changing epidemiology of rubella in the 1990s: On the verge of elimination and new challenges for control and prevention. JAMA 2002; 287: 464-472.
17. Reef SE, Redd SB, Abernathy E, Zimmerman L, Icenogle JP. The epidemiological profile of rubella and congenital rubella syndrome in the United States, 1998-2004: The evidence for absence of endemic transmission. Clin Infect Dis 2006; 43 (Suppl 3): S126-S132.
18. Okuda M, Yamanaka M, Takahashi T, Ishikawa H, Endoh M, Hirahara F. Positive rates for rubella antibody in pregnant women and benefit of post-partum vaccination in a Japanese perinatal center. J Obstet Gynaecol Res 2008; 34: 168-173.
19. Kenneson A, Cannon MJ. Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection. Rev Med Virol 2007; 17: 253-276.
20. Yamashita M, Kobayashi T, Yonezawa M, Ueda S. A prospective study on congenital cytomegalovirus infection. Jpn J Obstet Gynecol Neonatal Hematol 1996; 6: 67-74.
21. Guerra B, Lazzarotto T, Quarta S, Lanari M, Bovicelli L, Nicolosi A. Prenatal diagnosis of symptomatic congenital cytomegalovirus infection. Am J Obstet Gynecol 2000; 183: 476-482.
22. Azam AZ, Vial Y, Fawer CL, Zufferey J, Hohlfeld P. Prenatal diagnosis of congenital cytomegalovirus infection. Obstet Gynecol 2001; 97: 443-448.
23. Liesnard C, Donner C, Brancart F, Gosselin F, Delforge ML, Rodesch F. Prenatal diagnosis of congenital cytomegalovirus infection: Prospective study of 237 pregnancies at risk. Obstet Gynecol 2000; 95: 881-888.
24. Lipitz S, Achiron R, Zalel Y, Mendelson E, Tepperberg M, Gamzu R. Outcome of pregnancies with vertical transmission of primary cytomegalovirus infection. Obstet Gynecol 2002; 100: 428-433.
25. Hagay ZJ, Biran G, Ornoy A, Reece EA. Congenital cytomegalovirus infection: A long-standing problem still seeking a solution. Am J Obstet Gynecol 1996; 174: 241-245.
26. Screening for congenital CMV [Editorial]. Lancet 1989; 2: 599-600.
27. Gonce A, Marcos MA, Borrell A et al. Maternal IgM antibody status in confirmed fetal cytomegalovirus infection detected by sonographic signs. Prenat Diagn 2012; 32: 1-5.
28. Wang C, Zhang X, Bialek S, Cannon MJ. Attribution of congenital cytomegalovirus infection to primary versus nonprimary maternal infection. Clin Infect Dis 2011; 52: e11-e13.